PLoS ONE 9(6): e99880. doi:10.1371/journal.pone.0099880
Published June 17, 2014
16-17 march 2015, Geneva, Switzerland
Meeting report
Evaluation report
September 2014
Guidance Note. The recommended actions are presented under the different components (water supply, hygiene and hand washing, disinfection, solid waste management, latrine and wastewater management, and dead body management) of the defined Ebola Care Centre/Unit WASH package to complement community a...nd house-to-house level interventions
more
This guidance package compiles current facts and key messages about the Ebola outbreak in Liberia to inform activities designed to raise awareness, mobilize communities, and promote safe behaviors to stop the spread of Ebola in Liberia.
The toolkit aims to provide researchers with guidance for improving the quality of studies that use administrative data to better ascertain child maltreatment incidence, response and service delivery. However, these are complex studies to conduct, and the toolkit is not meant to be comprehensive. Re...searchers using the toolkit should be prepared to follow up on the recommended resources contained within and to consult with other professionals, such as statisticians, to further improve the research design and execution
more
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more